Acorah Software Products - Accounts Production 19.3.550 false true true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 08888419 Mr Geoffroy Berbesson Mr Thierry Degroote Dealbydeal Invest Mr Bertrand Pivin Mr Franck Legoux Mr Thomas Joly iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08888419 2024-12-31 08888419 2025-12-31 08888419 2025-01-01 2025-12-31 08888419 frs-core:CurrentFinancialInstruments 2025-12-31 08888419 frs-core:Non-currentFinancialInstruments 2025-12-31 08888419 frs-core:CapitalRedemptionReserve 2025-12-31 08888419 frs-core:SharePremium 2025-12-31 08888419 frs-core:ShareCapital 2025-12-31 08888419 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 08888419 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 08888419 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 08888419 frs-bus:SmallEntities 2025-01-01 2025-12-31 08888419 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 08888419 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 08888419 frs-core:CostValuation 2024-12-31 08888419 frs-core:AdditionsToInvestments 2025-12-31 08888419 frs-core:CostValuation 2025-12-31 08888419 frs-core:ProvisionsForImpairmentInvestments 2024-12-31 08888419 frs-core:ProvisionsForImpairmentInvestments 2025-12-31 08888419 frs-bus:Director1 2025-01-01 2025-12-31 08888419 frs-bus:Director2 2025-01-01 2025-12-31 08888419 frs-bus:Director3 2025-01-01 2025-12-31 08888419 frs-bus:Director4 2025-01-01 2025-12-31 08888419 frs-bus:Director5 2025-01-01 2025-12-31 08888419 frs-bus:Director6 2025-01-01 2025-12-31 08888419 frs-countries:EnglandWales 2025-01-01 2025-12-31 08888419 2023-12-31 08888419 2024-12-31 08888419 2024-01-01 2024-12-31 08888419 frs-core:CurrentFinancialInstruments 2024-12-31 08888419 frs-core:Non-currentFinancialInstruments 2024-12-31 08888419 frs-core:CapitalRedemptionReserve 2024-12-31 08888419 frs-core:SharePremium 2024-12-31 08888419 frs-core:ShareCapital 2024-12-31 08888419 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31
Registered number: 08888419
Medcube Limited
Unaudited Financial Statements
For The Year Ended 31 December 2025
Contents
Page
Company Information 1
Balance Sheet 2—3
Notes to the Financial Statements 4—6
Page 1
Company Information
Directors Mr Geoffroy Berbesson
Mr Thierry Degroote
Dealbydeal Invest
Mr Bertrand Pivin
Mr Franck Legoux
Mr Thomas Joly
Company Number 08888419
Registered Office The Scalpel, 18th Floor
52 Lime Street
London
United Kingdom
EC3M 7AF
Page 1
Page 2
Balance Sheet
Registered number: 08888419
2025 2024
as restated
Notes € € € €
FIXED ASSETS
Investments 4 605,891 576,960
605,891 576,960
CURRENT ASSETS
Debtors 5 8,456,587 7,973,536
Cash at bank and in hand 32,925 25,439
8,489,512 7,998,975
Creditors: Amounts Falling Due Within One Year 6 (7,636 ) (2,621,540 )
NET CURRENT ASSETS (LIABILITIES) 8,481,876 5,377,435
TOTAL ASSETS LESS CURRENT LIABILITIES 9,087,767 5,954,395
NET ASSETS 9,087,767 5,954,395
CAPITAL AND RESERVES
Called up share capital 1,356,409 1,159,056
Share premium account 9,539,056 6,558,011
Capital redemption reserve (23,451 ) (23,451 )
Profit and Loss Account (1,784,247 ) (1,739,221 )
SHAREHOLDERS' FUNDS 9,087,767 5,954,395
Page 2
Page 3
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Franck Legoux
Director
Mr Thomas Joly
Director
18 September 2026
The notes on pages 4 to 6 form part of these financial statements.
Page 3
Page 4
Notes to the Financial Statements
1. General Information
Medcube Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08888419 . The registered office is The Scalpel, 18th Floor, 52 Lime Street, London, United Kingdom, EC3M 7AF.

These financial statements were authorised for issue by the Board on 29/09/2025.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities — "The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland" and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
The functional and presentational currency of the financial statements is Euros (€).
2.2. Going Concern Disclosure
The accounts have been prepared on a going concern basis.
The directors, having made such enquiries as they considered appropriate and having a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, have prepared the financial statements on a going concern basis. The financial statements do not include any adjustments that would result from withdrawal of this support
2.3. Significant judgements and estimations
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses, and the disclosure of contingent assets and liabilities. These estimates and judgements are based on historical experience and other factors considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
The critical judgements made by management that have a significant effect on the amounts recognised in the financial statements are described below.
The accounting treatment of the convertible bonds requires management to exercise judgement in assessing the appropriate classification and measurement of the instrument, including the treatment of the embedded conversion feature and the determination of an appropriate market rate of interest for discounting purposes on initial recognition.
A rate of 5% has been applied, based on management’s assessment of a comparable market rate for a similar instrument with equivalent risk characteristics and term.
2.4. Financial Instruments
The company recognizes financial assets and liabilities when it becomes a party to the contractual provisions of the instrument.
Financial assets comprise of other debtors including convertible bonds. These are non-basic financial instruments, with the bond receivable initially recognised at amortised cost using a market rate of interest, with any variance between amortised cost and the transaction value recognised as a derivative asset accounted for at fair value through profit or loss or an investment held at cost less amortisation where the conversion feature relates to an existing investment and thus viewed as part of the shareholder return profile rather than a separable derivative held for trading.  Financial liabilities comprise trade and other creditors including convertible loan notes which are measured at amortised cost.
2.5. Foreign Currencies
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2.6. Taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Page 4
Page 5
2.7. Share Capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of cash or other resources received or receivable, net of direct costs of issuing equity instruments. If payment is deferred and time value of money is material, initial measurement is on a present value basis.
2.8. Investments
Investments in group undertakings are held at cost less provisions for impairment.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Investments
Other
€
Cost or Valuation
As at 1 January 2025 576,960
Additions 28,931
As at 31 December 2025 605,891
Provision
As at 1 January 2025 -
As at 31 December 2025 -
Net Book Value
As at 31 December 2025 605,891
As at 1 January 2025 576,960
Included within fixed asset investments is €585,891 (2024: €556,960) in respect of the company’s investment in Eurodonti S.A, acquired in 2021. The investment comprises amounts paid to acquire usufruct rights which provide the company with control over the undertaking, together with additional investment recognised on the provision of below-market financing provided Eurodonti S.A representing the difference between the loan’s nominal amount and its fair value on initial recognition.
5. Debtors
2025 2024
as restated
€ €
Due within one year
Other debtors 804,951 -
Due after more than one year
Other debtors 7,651,636 7,973,536
8,456,587 7,973,536
Included within other debtors is €8,456,587 (2024: €7,973,536) in respect of convertible bonds issued by Eurodonti S.A, a controlled undertaking of the company by virtue of its usufruct rights, of which €804,951(2024: €nil) is due within one year and €7,651,636 (2024: €7,973,536) is due after more than one year.  The bonds are contractually interest-bearing at 4%; however, the interest was formally waived in full during both the current and comparative periods. The bonds are carried at amortised cost with a contractual maturity of seven years from issuance and discounted using a market rate of interest of 5% per annum.
Page 5
Page 6
6. Creditors: Amounts Falling Due Within One Year
2025 2024
as restated
€ €
Trade creditors 2,000 -
Other loans 1,375 2,610,593
Accruals 4,261 10,947
7,636 2,621,540
Other loans in the prior year included convertible loan notes of €2,609,968 bearing interest at 17.5% per annum. During the year, the loan notes, together with interest accrued up to the date of conversion, were converted into 167,996 B Ordinary shares on 31 March 2025 at a conversion price of €16.18 per share. 
Page 6